Use of Chaetocin and Related Compounds as Cancer Therapeutics

Reference #:

2005-048

Inventors/Contributors

Keith C. Bible M.D., Ph.D., Crescent R. Isham B.S., Ruifang Xu M.D., Ph.D., Jennifer D. Tibodeau Ph.D.

Description

Chaetocin, a previously identified fungal byproduct, was found to kill cancer cells at low nanomolar drug concentrations. In particular, lung cancer, breast cancer, colon cancer, multiple myeloma, sarcoma and other cancer cells were readily killed by exposure to chaetocin for 24 hours or less at concentrations well below those reported to produce toxicity by related compounds in mammals. Mayo Clinic researchers are further developing chaetocin and related compounds as therapeutics for multiple myeloma (see "Chaetocin: A Promising New Antimyelona Agent with In Vitro and In Vivo Activity Mediated via Imposition of Oxidative Stress," Blood. 109 (6): 2579-88, 2007 Mar 15.)

Patent Status

Pending